Recurrent ovarian undifferentiated carcinoma resembling hepatoid morphology treated with pegylated liposomal doxorubicin and bevacizumab. Issue 5 (19th April 2017)

• Record Type: Journal Article
• Authors: Ishiguro, Tatsuya; Kashima, Kastunori; Yachida, Nozomi; Motoyama, Teiichi; Enomoto, Takayuki
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 43:Issue 5(2017)
• Page Start: 957
• Page End: 961
• Publication Date: 2017-04-19
• Subjects: α‐fetoprotein -- bevacizumab -- chemotherapy -- hepatoid carcinoma -- ovarian cancer; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13298
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Hepatoid carcinomas are undifferentiated epithelial carcinomas that are pathologically similar to hepatocellular carcinoma, but occur in a variety of organs. Hepatoid carcinomas, as strictly defined, typically produce α‐fetoprotein. In addition, a standard effective chemotherapy regimen for hepatoid carcinoma has yet to be established. We present a case of advanced primary ovarian cancer that was pathologically similar to hepatoid carcinoma without staining for α‐fetoprotein or hepatocyte paraffin 1. The primary ovarian, metastatic, and recurrent tumors shared similar pathological characteristics. Fourth‐line chemotherapy with pegylated liposomal doxorubicin and bevacizumab was effective in treating the recurrent tumor, even though this disease had recurred three times.